1. |
Kang S1, Koh ES, Vinod SK, et al. Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol, 2012, 56 (2):235-241.
|
2. |
Tomita Y, Morioka E, Kaida D, et al. A case of port site recurrence after thoracoscopic resection for lung metastasis of cecal cancer. Gan To Kagaku Ryoho, 2012, 39 (12):1923-1925.
|
3. |
Oji Y, Kitamura Y, Kamino E, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer, 2009, 125 (2):381-387.
|
4. |
Le Tonqueze O, Gschloessl B, Namanda-Vanderbeken A, et al. Chromosome wide analysis of CUGBP1 binding sites identifies the tetraspanin CD9 mRNA as a target for CUGBP1-mediated down-regul ation. Biochem Biophys Res Commun, 2010, 394 (4):884-889.
|
5. |
Timchenko LT, Miller JW, Timchenko NA, et al. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res, 1996, 24 (22):4407-4414.
|
6. |
Souza D, Lai RY, Shuen M, et al. mRNA stability as a function of striated muscle oxidative capacity. Am J Physiol Regul Integr Comp Physiol, 2012, 303 (4):408-417.
|
7. |
Zhang L, Lee JE, Wilusz J, et al. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells:implications for myotonic dystrophy. J Biol Chem, 2008, 283 (33):22457-22463.
|
8. |
Zheng Y, Miskimins WK. CUG-binding protein represses translation of p27Kip1 mRNA through its internal ribosomal entry site. RNA Biol, 2011, 8 (3):365-371.
|
9. |
Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans, 2009, 37 (6):1281-1286.
|
10. |
De La Motte Rouge T, Valent A, Ambrosetti D, et al. Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Ann Pathol, 2007, 27 (5):353-363.
|
11. |
Benlloch S, Galbis-Caravajal JM, Alenda C, et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC):prognostic impact and potential role as markers of occult micrometastases. Ann Oncol, 2009, 20 (1):91-97.
|
12. |
Cui YH, Xiao L, Rao JN, et al. miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell, 2012, 23 (1):151-162.
|
13. |
Meola G, Jones K, Wei C, et al. Dysfunction of protein homeostasis in myotonic dystrophies. Histol Histopathol, 2013, 28 (9):1089-1098.
|
14. |
Beisang D, Rattenbacher B, Vlasova-St Louis IA, et al. Regulation of CUG-binding protein 1 (CUGBP1)binding to target transcripts upon T cell activation. J Biol Chem, 2012, 287 (2):950-960.
|
15. |
Xiao L, Cui YH, Rao JN, et al. Regulation of cyclin-dependent kinase 4 translation through CUG-binding protein 1 and microRNA-222 by polyamines. Mol Biol Cell, 2011, 22(17):3055-3069.
|
16. |
Huichalaf C, Sakai K, Jin B, et al. Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1)cells. FASEB J, 2010, 24 (10):3706-3719.
|
17. |
Salisbury E, Sakai K, Schoser B, et al. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res, 2008, 314 (11-12):2266-2278.
|
18. |
Arnal-Estape A, Tarragona M, Morales M, et al. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res, 2010, 70 (23):9927-9936.
|
19. |
Rattenbacher B, Beisang D, Wiesner DL, et al. Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Mol Cell Biol, 2010, 30 (16):3970-3980.
|
20. |
代学利, 申屠阳. Ⅰb期非小细胞肺癌患者手术预后因素分析.中国胸心血管外科临床杂志, 2009, 16 (5):353-356.
|